Literature DB >> 25358689

The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints.

Nicolas J Llosa1, Michael Cruise2, Ada Tam3, Elizabeth C Wicks4, Elizabeth M Hechenbleikner4, Janis M Taube2, Richard L Blosser3, Hongni Fan1, Hao Wang5, Brandon S Luber5, Ming Zhang6, Nickolas Papadopoulos6, Kenneth W Kinzler6, Bert Vogelstein6, Cynthia L Sears7, Robert A Anders2, Drew M Pardoll8, Franck Housseau9.   

Abstract

UNLABELLED: We examined the immune microenvironment of primary colorectal cancer using immunohistochemistry, laser capture microdissection/qRT-PCR, flow cytometry, and functional analysis of tumor-infiltrating lymphocytes. A subset of colorectal cancer displayed high infiltration with activated CD8(+) cytotoxic T lymphocyte (CTL) as well as activated Th1 cells characterized by IFNγ production and the Th1 transcription factor TBET. Parallel analysis of tumor genotypes revealed that virtually all of the tumors with this active Th1/CTL microenvironment had defects in mismatch repair, as evidenced by microsatellite instability (MSI). Counterbalancing this active Th1/CTL microenvironment, MSI tumors selectively demonstrated highly upregulated expression of multiple immune checkpoints, including five-PD-1, PD-L1, CTLA-4, LAG-3, and IDO-currently being targeted clinically with inhibitors. These findings link tumor genotype with the immune microenvironment, and explain why MSI tumors are not naturally eliminated despite a hostile Th1/CTL microenvironment. They further suggest that blockade of specific checkpoints may be selectively efficacious in the MSI subset of colorectal cancer. SIGNIFICANCE: The findings reported in this article are the first to demonstrate a link between a genetically defined subtype of cancer and its corresponding expression of immune checkpoints in the tumor microenvironment. The mismatch repair-defective subset of colorectal cancer selectively upregulates at least five checkpoint molecules that are targets of inhibitors currently being clinically tested. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2014        PMID: 25358689      PMCID: PMC4293246          DOI: 10.1158/2159-8290.CD-14-0863

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  25 in total

Review 1.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 2.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

3.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability.

Authors:  R Dolcetti; A Viel; C Doglioni; A Russo; M Guidoboni; E Capozzi; N Vecchiato; E Macrì; M Fornasarig; M Boiocchi
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

4.  Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.

Authors:  Janis M Taube; Alison Klein; Julie R Brahmer; Haiying Xu; Xiaoyu Pan; Jung H Kim; Lieping Chen; Drew M Pardoll; Suzanne L Topalian; Robert A Anders
Journal:  Clin Cancer Res       Date:  2014-04-08       Impact factor: 12.531

Review 5.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

6.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

Review 7.  Th17 cells in cancer: help or hindrance?

Authors:  Cailin Moira Wilke; Ilona Kryczek; Shuang Wei; Ende Zhao; Ke Wu; Guobin Wang; Weiping Zou
Journal:  Carcinogenesis       Date:  2011-02-08       Impact factor: 4.944

8.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer.

Authors:  Marie Tosolini; Amos Kirilovsky; Bernhard Mlecnik; Tessa Fredriksen; Stéphanie Mauger; Gabriela Bindea; Anne Berger; Patrick Bruneval; Wolf-Herman Fridman; Franck Pagès; Jérôme Galon
Journal:  Cancer Res       Date:  2011-02-08       Impact factor: 12.701

9.  Epitope landscape in breast and colorectal cancer.

Authors:  Neil H Segal; D Williams Parsons; Karl S Peggs; Victor Velculescu; Ken W Kinzler; Bert Vogelstein; James P Allison
Journal:  Cancer Res       Date:  2008-02-01       Impact factor: 12.701

10.  Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection.

Authors:  Charlly Kao; Kenneth J Oestreich; Michael A Paley; Alison Crawford; Jill M Angelosanto; Mohammed-Alkhatim A Ali; Andrew M Intlekofer; Jeremy M Boss; Steven L Reiner; Amy S Weinmann; E John Wherry
Journal:  Nat Immunol       Date:  2011-05-29       Impact factor: 25.606

View more
  537 in total

1.  MicroRNA MIR21 and T Cells in Colorectal Cancer.

Authors:  Kosuke Mima; Reiko Nishihara; Jonathan A Nowak; Sun A Kim; Mingyang Song; Kentaro Inamura; Yasutaka Sukawa; Atsuhiro Masuda; Juhong Yang; Ruoxu Dou; Katsuhiko Nosho; Hideo Baba; Edward L Giovannucci; Michaela Bowden; Massimo Loda; Marios Giannakis; Adam J Bass; Glenn Dranoff; Gordon J Freeman; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151

Review 2.  Immune cell interplay in colorectal cancer prognosis.

Authors:  Samuel E Norton; Kirsten A Ward-Hartstonge; Edward S Taylor; Roslyn A Kemp
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

Review 3.  Targeted therapy for advanced gastric cancer: A review of current status and future prospects.

Authors:  Ozkan Kanat; Bert O'Neil; Safi Shahda
Journal:  World J Gastrointest Oncol       Date:  2015-12-15

Review 4.  New therapeutic strategies for BRAF mutant colorectal cancers.

Authors:  Ryan B Corcoran
Journal:  J Gastrointest Oncol       Date:  2015-12

Review 5.  Emerging cytokine networks in colorectal cancer.

Authors:  Nathan R West; Sarah McCuaig; Fanny Franchini; Fiona Powrie
Journal:  Nat Rev Immunol       Date:  2015-09-11       Impact factor: 53.106

6.  Mismatch repair deficient metastatic colon cancer and urothelial cancer: A case report of sequential immune checkpoint therapy.

Authors:  Pooja Ghatalia; Rajeswari Nagarathinam; Harry Cooper; Daniel M Geynisman; Wafik S El-Deiry
Journal:  Cancer Biol Ther       Date:  2017-07-20       Impact factor: 4.742

7.  TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection.

Authors:  Apostolos Klinakis; Theodoros Rampias
Journal:  EBioMedicine       Date:  2020-07-30       Impact factor: 8.143

Review 8.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

Review 9.  DNA repair defects and implications for immunotherapy.

Authors:  Katherine M Bever; Dung T Le
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

10.  Tumor Molecular Testing Guides Anti-PD-1 Therapy and Provides Evidence for Pathogenicity of Mismatch Repair Variants.

Authors:  Shyam A Patel; Teri A Longacre; Uri Ladabaum; Alexandra Lebensohn; Albert Y Lin; Sigurdis Haraldsdottir
Journal:  Oncologist       Date:  2018-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.